KYTX (Kyverna Therapeutics) Interest Expense: $-1.13 Mil (TTM As of Mar. 2026)


KYTX Kyverna Therapeutics Inc KYTX
12 GF Score
Price $9.67
! 2 Warning Signs
View Full Analysis

What is Kyverna Therapeutics Interest Expense?

Kyverna Therapeutics KYTX +5.62% 12 Interest Expense is $-1.13 Mil as of Mar. 2026. GuruFocus rates KYTX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Kyverna Therapeutics's interest expense for the three months ended in Mar. 2026 was $ -0.67 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.13 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Kyverna Therapeutics's Operating Income for the three months ended in Mar. 2026 was $ -41.37 Mil. Kyverna Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $ -0.67 Mil. Kyverna Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kyverna Therapeutics  (NAS:KYTX) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kyverna Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $-0.67 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-41.37 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $31.77 Mil.

Kyverna Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Kyverna Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Kyverna Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Kyverna Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyverna Therapeutics Interest Expense Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
-0.00 -0.07 -0.19 -0.14 -0.49

Kyverna Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.01 -0.01 -0.44 -0.67
KYTX
12GF Score
Kyverna Therapeutics Inc KYTX
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyverna Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-1.13 Mil mean?
Kyverna Therapeutics (KYTX) has a Interest Expense of $-1.13 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Kyverna Therapeutics and its competitors.
Is Kyverna Therapeutics' Interest Expense too high?
Kyverna Therapeutics' current Interest Expense is $-1.13 Mil. Overall, Kyverna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kyverna Therapeutics' Interest Expense compare to ZURA and CBIO?
Kyverna Therapeutics' Interest Expense of $-1.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Kyverna Therapeutics and its competitors. Kyverna Therapeutics's current Interest Expense is $-1.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyverna Therapeutics stock overvalued right now?
Kyverna Therapeutics (KYTX) has a current Interest Expense of $-1.13 Mil. The current Interest Expense is $-1.13 Mil. Kyverna Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Kyverna Therapeutics (KYTX), the current Interest Expense is $-1.13 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kyverna Therapeutics Business Description

Address 5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
12GF Score

Get the complete analysis for KYTX

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.67
Price